Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

Company Performance - Prime Medicine, Inc. reported a quarterly loss of $0.40 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.32, representing an earnings surprise of -25% [1] - The company posted revenues of $1.45 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 68.25%, compared to revenues of $0.59 million a year ago [2] - Over the last four quarters, Prime Medicine has surpassed consensus EPS estimates only once and has not beaten consensus revenue estimates during the same period [2] Stock Movement and Outlook - Prime Medicine shares have declined approximately 51.4% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$0.31 on revenues of $4.58 million, and for the current fiscal year, it is -$1.22 on revenues of $14.17 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Prime Medicine belongs, is currently in the top 33% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Prime Medicine's stock performance [5]